Dermatology Life Quality Index
- Introduced by
- Andrew Y. Finlay and Gul K. Khan
- Year
- 1994
- Type
- Self-report quality of life questionnaire
- Family
- Dermatology and Skin Disease
What does it do?
The DLQI is the primary patient-centered outcome measure in dermatology research and clinical practice.
Developed by Andrew Finlay and Gul Khan in 1994, this 10-item self-report questionnaire quantifies the impact of skin disease on patients' daily functioning, emotional well-being, social relationships, and work capacity. It is simple, rapid, and applicable to virtually all dermatological conditions, making it the gold standard for assessing quality of life in dermatology.
The intuition behind the method
Skin disease affects far more than skin. Visible dermatological conditions trigger psychological distress, social withdrawal, and functional impairment that may exceed the physical symptom burden. A patient with psoriasis covering 5% of body surface area might experience greater depression and isolation than the clinical severity suggests, while another with extensive but hidden eczema may report minimal quality-of-life impact. The DLQI captures this patient perspective by asking directly about how skin disease affects daily activities, emotions, social contact, clothing choices, work, and leisure. Its brevity (10 items, 1 minute to answer) makes it feasible in busy dermatology clinics while remaining sensitive to clinically meaningful changes.
History
The DLQI was developed in 1994 by Andrew Y. Finlay and Gul K. Khan at the Wales Dermatology Centre, University of Wales. The need arose from recognition that dermatological outcomes, unlike internal medicine, cannot be assessed adequately by clinician observation alone; patient perception and functional impact are central. The original paper (Clinical and Experimental Dermatology, 1994) reported initial reliability and validity. Subsequent decades saw extensive translation (80+ languages), validation across skin conditions, and periodic refinement. A pediatric version (cDLQI, for ages 4-16) was introduced, and adapted versions exist for specific conditions (e.g., vitiligo-specific, occupational dermatitis-specific). The DLQI has become the most-cited dermatology outcome measure and is recommended by dermatology societies worldwide.
When to use it
The DLQI is indicated in any dermatology clinical or research setting where patient quality of life is relevant. This includes assessing impact at baseline to guide treatment planning, monitoring response to therapy (improvement in quality of life alongside or sometimes preceding clinical improvement), comparing treatment options, evaluating new drugs in trials, audit and quality improvement in dermatology services, and examining long-term consequences of chronic skin disease. It is appropriate for all skin conditions (eczema, psoriasis, acne, vitiligo, alopecia, rosacea, etc.). It is not appropriate for non-dermatological conditions, though skin manifestations of systemic disease (e.g., lupus) can be assessed.
Limitations and considerations
- Limited symptom depth—does not assess specific symptoms (itch, pain, weeping) in detail; if symptom characterization is needed, disease-specific symptom scales must be added
- No diagnostic capability—measures impact but does not diagnose skin disease or comorbidities (depression, anxiety); supplementary instruments necessary for diagnosis
- Score interpretation depends on disease context—the clinical meaning of a DLQI of 8 differs for acute contact dermatitis (expected short-term) versus severe psoriasis (chronic); reference values and disease-specific norms aid interpretation
- Assumes stable conditions—designed for conditions with relatively stable manifestations; rapidly fluctuating acute conditions may generate variable scores unrelated to true quality-of-life change
- Not validated in children <16 years—use Children's DLQI (cDLQI) for younger patients; DLQI responses may not reliably reflect quality of life in very young children
Source conditions do not replace independent scientific review or validation by an analysis engine.
Strengths
- Brevity and feasibility—10 items, 1-2 minute completion time, compatible with routine clinical practice without imposing burden on patients or clinicians
- Strong validity—extensively validated across 80+ languages and dermatological conditions, showing good discriminant validity between disease severities and responsiveness to treatment
- Patient-centered—developed directly from patient interviews and priorities, measuring outcomes patients care about
- Internationally standardized—DLQI guidelines ensure consistent administration and interpretation worldwide; endorsed by major dermatology societies
- Free to use—unrestricted access for clinical and research use; no copyright restrictions limiting adoption
- Weak disease-severity correlation—demonstrates that quality of life is independent of objective clinical measures, justifying its use as a co-primary endpoint in trials
Applications
- Clinical trial design: A randomized controlled trial of dupilumab for moderate-to-severe atopic dermatitis used DLQI as a co-primary endpoint alongside clinician-rated Eczema Area and Severity Index (EASI), demonstrating that patients' lived experience, not just clinician assessment, drives regulatory approval for new drugs.
- Acne in adolescents: A prospective study of 200 acne patients found mean baseline DLQI 13.2, with psychological impact (embarrassment, social anxiety) dominating clinical severity; treatment decisions for acne should therefore weigh psychological distress, best captured by DLQI, not acne grade alone.
- Vitiligo and body image: A cross-cultural analysis comparing vitiligo patients in India, UK, and Japan revealed striking variation in DLQI despite similar objective disease extent, pointing to cultural differences in appearance concern; DLQI revealed these nuances better than clinical measures.
- Occupational dermatitis in healthcare workers: During the COVID-19 pandemic, hand dermatitis from frequent hand sanitizer use showed DLQI scores of 8-15, prompting occupational health services to provide protective and restorative interventions (gloves, emollients), validated by DLQI improvement tracking adherence to prevention.
How it works
How it works
The DLQI comprises 10 items, each with four response options (0=Not at all/Not applicable, 1=A little, 2=A lot, 3=Very much). Items address activities/symptoms, emotions, relationships, work/school, and leisure over the past week. Self-administered, typically completed in 1-2 minutes. Paper and digital versions exist. Validated in 80+ languages. Appropriate for patients aged 16 and older; a pediatric version (Children's DLQI) exists for ages 4-16.
Each item is scored 0-3. Items with not applicable responses are assigned zero. Total DLQI = sum of all 10 items, ranging 0-30. Reverse-coded items are not used. A higher score indicates greater impairment.
DLQI score interpretation: 0-1 = no effect on patient's life; 2-5 = small effect; 6-10 = moderate effect; 11-20 = very large effect; 21-30 = extremely large effect. These bands were derived empirically from clinical observation. A change of ≥4 points is considered clinically significant. Baseline DLQI correlates weakly to moderately with objective disease severity (e.g., PASI for psoriasis), underscoring the importance of patient self-assessment.
Common pitfalls
- Over-interpreting small absolute scores as 'no problem'—a DLQI of 3 still represents measurable life disruption; whether it warrants intervention depends on patient priorities and available treatments, not the score alone
- Comparing DLQI across unrelated skin conditions without disease-specific context—a DLQI of 10 in acne (often highly distressing to adolescents) has different implications than a DLQI of 10 in mild hand eczema; use disease-specific norms when available
- Assuming DLQI correlates with clinical severity—it does not; a patient with extensive psoriasis might report DLQI 5 if managed well psychologically, while one with limited vitiligo might report DLQI 18 due to psychological impact; never use DLQI alone to assess disease severity
- Misapplying scoring rules for 'not applicable' items—these should be coded zero, not skipped; improper handling inflates or deflates total scores
- Ignoring temporal context—DLQI asks about the past week; a patient assessed during acute disease flare will score differently than during remission; always note assessment timing
Frequently asked questions
How is DLQI interpreted for acute versus chronic skin disease?
For acute conditions (e.g., contact dermatitis, acute urticaria), DLQI quantifies temporary disruption; a DLQI of 12 might be clinically acceptable if expected to resolve in days to weeks. For chronic conditions (e.g., psoriasis, atopic dermatitis), the same DLQI of 12 represents ongoing burden and typically warrants aggressive treatment. Always consider disease duration when interpreting DLQI scores.
Does DLQI score correlate with clinical severity (e.g., PASI for psoriasis)?
Correlation is weak to modest (typically r = 0.30-0.50). Many patients with extensive disease report low DLQI (good coping, mild psychological impact), while others with limited disease report high DLQI (severe cosmetic or itch distress). This independence justifies using DLQI as a separate outcome measure alongside clinical severity.
What constitutes a clinically significant DLQI change during treatment?
A change of ≥4 points is considered clinically meaningful. Improvement from DLQI 15 to 11 represents meaningful benefit. The magnitude of meaningful change may vary by baseline severity and condition; disease-specific studies sometimes define context-specific minimally important differences.
Is DLQI suitable for assessing systemic diseases with skin manifestations?
DLQI can quantify life impact from skin symptoms in systemic diseases (e.g., lupus cutaneous manifestations, scleroderma-associated skin tightness), but it does not measure systemic disease burden. Combine DLQI with systemic disease-specific measures (e.g., SLE disease activity index) for comprehensive assessment.
Related methods
Sources
Finlay, A. Y., & Khan, G. K. (1994). Dermatology Life Quality Index (DLQI): A simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 19(3), 210-216.
Open DOI referenceCopied.Hongbo, Y., Thomas, C. L., Harrison, M. A., Salek, M. S., & Finlay, A. Y. (2005). Translating the science of quality of life into practice: What do dermatology patients' need? Dermatologic Clinics, 23(4), 675-684.
Open publication referenceCopied.Basra, M. K., Fenech, R., Gatt, R. M., Salek, M. S., & Finlay, A. Y. (2008). The Dermatology Life Quality Index 1994-2007: A review of instrument evolution and application. British Journal of Dermatology, 159(5), 997-1035.
Open publication referenceCopied.